Microdosing vs macrodosing GLP-1 comes down to one structural choice: whether you take the whole week's medication at once or spread a smaller total across several smaller injections. That choice changes the shape of your blood levels, and the shape of your blood levels is what you actually feel. Here's what each approach does, what the evidence supports, and who tends to do better on which.
What's the difference between microdosing and macrodosing a GLP-1?
The difference isn't only about comfort. A single weekly dose produces a high concentration in the first 48 hours, then a gradual decline. Plenty of patients describe feeling rough for two days, fine for three, and then noticing food noise and hunger coming back by day five or six. Splitting the dose flattens that curve.
| Factor | Macrodosing (standard titration) | Microdosing |
|---|---|---|
| Dose range | Labelled schedule. Semaglutide starts at 0.25 mg weekly and titrates every four weeks toward 2.4 mg | Lowest effective total dose, kept well below the labelled maximum |
| Frequency | Once weekly | Twice weekly or more often |
| Blood level pattern | Peak within 48 hours, then a decline before the next dose | Steadier, with smaller swings across the week |
| Side effect profile | Higher, and concentrated in the days after each injection and each step up | Generally lower, since peak concentrations are lower |
| Muscle preservation | No head-to-head data. Faster weight loss puts more pressure on protein intake and training | No head-to-head data. Slower loss gives more room to protect lean mass, but only if you do the work |
| Cost | Rises at each titration step where pricing is dose-based | Usually lower per month on medication, with more injection supplies |
| Evidence base | The schedule used in the large randomised trials | Clinical practice and patient-reported outcomes, not randomised trials |
| Who it suits | Patients who tolerate titration well and want the fastest, best-documented result | Patients who've struggled with side effects, plateaued, or want a long-term approach |
Why the weekly spike and crash matters
Rapid dose escalation is the most common reason patients quit GLP-1 therapy. Introducing a large dose into a body that's already carrying metabolic stress or inflammation can produce nausea, vomiting, fatigue, and real gastrointestinal distress, and that response is a signal the system is overwhelmed rather than a rite of passage you have to push through.
An overwhelmed body also raises cortisol to cope, which is the same hormone that works against metabolic function. The medication ends up fighting itself. If you want the longer breakdown of what escalation costs over time, our post on why higher GLP-1 doses aren't always better long term covers it.
This isn't a new idea in hormone medicine. Standard testosterone protocols often use one large weekly injection that produces a spike, and patients who move to daily or every other day dosing usually report steadier energy instead of a good couple of days followed by a flat week. Our post on TRT for men and what to expect goes through how a well designed protocol is built.
The receptor sensitivity problem
Chronically high levels of any hormonal signal push the body's receptors to downregulate, which means they become less responsive over time. With GLP-1 therapy the clinical version of this is the plateau: the dose stops doing what it did, and increasing it produces less than it used to.
Microdosing works on the opposite principle. Using the lowest dose that still does the job is meant to keep receptor sensitivity intact rather than spend it. If you've already stalled on a standard protocol, our post on the GLP-1 receptor reset explains what's happening and what to do about it.
Not sure which dosing approach fits you?
A licensed clinician reviews your history and builds the protocol around it, rather than the other way round.
Take the assessment
What standard titration gets right
Standard weekly titration is the approach with the evidence behind it, and that matters. Every large randomised trial of these medications used the labelled schedule, so when you see a weight loss figure quoted, it came from macrodosing. In the STEP-1 trial published in the New England Journal of Medicine in 2021, participants on semaglutide 2.4 mg once weekly lost an average of 14.9% of body weight over 68 weeks alongside lifestyle support.
The four-week spacing between steps also isn't arbitrary. It's roughly how long the gastrointestinal system takes to adapt to a given dose, and it exists specifically to keep side effects manageable while you climb. Plenty of patients titrate on schedule, tolerate it fine, and get an excellent result. There's no reason to abandon an approach that's working for you, and no head-to-head trial exists showing microdosing matches those weight loss numbers.
Side effects and how they differ
Most GLP-1 side effects are gastrointestinal, and they're worst in the days right after an injection or a step up. That timing is the whole reason dose shape matters. The FDA prescribing information for Wegovy reports nausea in 44% of patients, diarrhoea in 23%, vomiting in 15%, and constipation in 11%.
Lower peak concentrations generally mean a milder version of the same effects, which is the practical argument for microdosing. It isn't a guarantee of no side effects.
Common side effects include:
- Nausea, especially in the first days after a dose or a dose increase
- Constipation or diarrhoea
- Reduced appetite and feeling full much sooner than usual
- Fatigue or mild headaches early on
- Mild redness or soreness at the injection site
Contact your provider if vomiting stops you keeping fluids down, or if you get severe abdominal pain that doesn't settle.
Who each approach suits
Microdosing tends to suit patients whose problem is tolerance or sustainability rather than potency. Standard titration tends to suit patients who handle the ramp well and want the most documented result in the shortest time.
Patients who tend to do better microdosing:
- Have tried a standard protocol and found the side effects disruptive to daily function
- Are dealing with cortisol dysregulation or ongoing metabolic stress
- Have plateaued on standard dosing despite sticking to it
- Are prioritising body composition and muscle preservation alongside weight loss, which our guide on preventing muscle loss on GLP-1 medications covers in detail
- Want a long-term approach rather than an aggressive short intervention
Patients who tend to do better on standard titration:
- Tolerate the first few dose steps without much trouble
- Have a significant amount of weight to lose and a clinical reason to move faster
- Want the protocol the trial evidence actually studied
- Prefer one injection a week to three or four
Frequently Asked Questions
Where to go from here
The standard protocol was built around maximum efficacy in a clinical trial. Microdosing is built around the patient who still has to work, look after their family, and function normally while they're treating something. Both are legitimate, and the right answer depends on how you respond, not on which one sounds better.
If you're new to the idea, start with our overview of what GLP-1 microdosing is, or the practical walkthrough in how to microdose semaglutide. Start the 2-minute assessment and a licensed clinician will review your information and recommend a starting plan.
Medical disclaimer. This article is for informational purposes only and does not constitute medical advice. GLP-1 medications are prescription-only and require evaluation by a licensed medical provider. Compounded medications are not FDA-approved. Results vary. Always consult a qualified healthcare provider before starting, changing, or stopping any treatment.
